Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALDX |
---|---|---|
09:32 ET | 10584 | 3.885 |
09:36 ET | 900 | 3.86 |
09:39 ET | 700 | 3.87 |
09:43 ET | 100 | 3.875 |
09:45 ET | 800 | 3.86 |
09:50 ET | 2207 | 3.86 |
09:52 ET | 1513 | 3.855 |
09:54 ET | 755 | 3.84 |
09:56 ET | 5604 | 3.85 |
09:57 ET | 900 | 3.85 |
09:59 ET | 179 | 3.8519 |
10:01 ET | 570 | 3.8638 |
10:08 ET | 590 | 3.8696 |
10:10 ET | 100 | 3.87 |
10:12 ET | 13291 | 3.885 |
10:14 ET | 600 | 3.89 |
10:15 ET | 350 | 3.885 |
10:17 ET | 260 | 3.885 |
10:19 ET | 1960 | 3.85 |
10:21 ET | 315 | 3.84 |
10:24 ET | 7451 | 3.84 |
10:26 ET | 400 | 3.84 |
10:32 ET | 200 | 3.84 |
10:33 ET | 200 | 3.84 |
10:35 ET | 100 | 3.84 |
10:39 ET | 1700 | 3.86 |
10:44 ET | 600 | 3.86 |
10:46 ET | 100 | 3.86 |
10:48 ET | 121 | 3.86 |
10:50 ET | 100 | 3.869 |
10:51 ET | 200 | 3.869 |
10:53 ET | 200 | 3.86 |
10:57 ET | 200 | 3.87 |
11:00 ET | 524 | 3.86 |
11:04 ET | 824 | 3.87 |
11:06 ET | 100 | 3.87 |
11:08 ET | 325 | 3.87 |
11:09 ET | 300 | 3.88 |
11:11 ET | 100 | 3.89 |
11:13 ET | 2495 | 3.89 |
11:15 ET | 100 | 3.9 |
11:18 ET | 253 | 3.896 |
11:20 ET | 600 | 3.92 |
11:22 ET | 100 | 3.92 |
11:24 ET | 100 | 3.919 |
11:26 ET | 312 | 3.919 |
11:27 ET | 100 | 3.919 |
11:29 ET | 100 | 3.919 |
11:31 ET | 100 | 3.919 |
11:33 ET | 100 | 3.92 |
11:36 ET | 1798 | 3.89 |
11:42 ET | 300 | 3.88 |
11:47 ET | 847 | 3.88 |
11:49 ET | 200 | 3.89 |
11:51 ET | 600 | 3.89 |
11:54 ET | 300 | 3.88 |
11:56 ET | 300 | 3.9 |
12:07 ET | 100 | 3.9 |
12:09 ET | 100 | 3.9 |
12:12 ET | 100 | 3.9 |
12:14 ET | 300 | 3.89 |
12:16 ET | 100 | 3.89 |
12:18 ET | 100 | 3.89 |
12:23 ET | 300 | 3.895 |
12:27 ET | 200 | 3.895 |
12:30 ET | 2479 | 3.8801 |
12:34 ET | 200 | 3.88 |
12:36 ET | 611 | 3.88 |
12:38 ET | 300 | 3.87 |
12:41 ET | 200 | 3.86 |
12:48 ET | 700 | 3.85 |
12:50 ET | 100 | 3.84 |
12:52 ET | 1135 | 3.8302 |
12:56 ET | 2199 | 3.845 |
12:57 ET | 2437 | 3.84 |
12:59 ET | 34958 | 3.83 |
01:06 ET | 100 | 3.84 |
01:10 ET | 300 | 3.84 |
01:12 ET | 1200 | 3.835 |
01:14 ET | 10092 | 3.83 |
01:15 ET | 300 | 3.83 |
01:17 ET | 645 | 3.82 |
01:21 ET | 731 | 3.82 |
01:28 ET | 100 | 3.825 |
01:30 ET | 100 | 3.825 |
01:32 ET | 2409 | 3.815 |
01:35 ET | 5300 | 3.835 |
01:37 ET | 1279 | 3.83 |
01:39 ET | 861 | 3.8394 |
01:42 ET | 1803 | 3.845 |
01:44 ET | 906 | 3.845 |
01:46 ET | 1335 | 3.84 |
01:50 ET | 2312 | 3.815 |
01:51 ET | 6528 | 3.83 |
01:55 ET | 100 | 3.81 |
01:57 ET | 100 | 3.81 |
02:00 ET | 3685 | 3.805 |
02:02 ET | 1295 | 3.7982 |
02:11 ET | 943 | 3.8 |
02:15 ET | 20031 | 3.85 |
02:18 ET | 1214 | 3.83 |
02:24 ET | 733 | 3.82 |
02:27 ET | 100 | 3.8 |
02:29 ET | 300 | 3.81 |
02:31 ET | 100 | 3.8 |
02:33 ET | 700 | 3.81 |
02:36 ET | 500 | 3.81 |
02:42 ET | 2300 | 3.82 |
02:44 ET | 910 | 3.82 |
02:45 ET | 7792 | 3.8 |
02:47 ET | 7165 | 3.79 |
02:49 ET | 500 | 3.79 |
02:51 ET | 200 | 3.79 |
02:54 ET | 600 | 3.78 |
02:56 ET | 300 | 3.79 |
03:00 ET | 600 | 3.79 |
03:02 ET | 300 | 3.8 |
03:05 ET | 400 | 3.8 |
03:07 ET | 5436 | 3.7964 |
03:09 ET | 100 | 3.8 |
03:12 ET | 3374 | 3.7819 |
03:20 ET | 1158 | 3.785 |
03:21 ET | 300 | 3.79 |
03:23 ET | 100 | 3.79 |
03:25 ET | 100 | 3.79 |
03:27 ET | 400 | 3.785 |
03:30 ET | 500 | 3.785 |
03:32 ET | 100 | 3.79 |
03:34 ET | 1948 | 3.795 |
03:36 ET | 200 | 3.8 |
03:38 ET | 100 | 3.8 |
03:39 ET | 594 | 3.795 |
03:41 ET | 4947 | 3.78 |
03:43 ET | 400 | 3.785 |
03:45 ET | 300 | 3.785 |
03:48 ET | 1200 | 3.785 |
03:50 ET | 300 | 3.78 |
03:52 ET | 587 | 3.78 |
03:54 ET | 700 | 3.785 |
03:56 ET | 729 | 3.785 |
03:57 ET | 8734 | 3.7898 |
03:59 ET | 5710 | 3.79 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Aldeyra Therapeutics Inc | 229.9M | -7.5x | --- |
Pyxis Oncology Inc | 229.7M | -2.8x | --- |
Eliem Therapeutics Inc | 228.9M | -13.9x | --- |
Ovid Therapeutics Inc | 229.2M | -4.2x | --- |
Prelude Therapeutics Inc | 226.3M | -2.1x | --- |
Design Therapeutics Inc | 235.0M | -3.9x | --- |
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $229.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.38 |
EPS | $-0.51 |
Book Value | $2.02 |
P/E Ratio | -7.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.